COVID-19 vaccine candidates secure funds; Lysol gets EPA nod
Published
Novavax has received $1.6 billion from the federal government to complete late-stage clinical development; establish large-scale manufacturing; and deliver 100 million doses of NVXâCoV2373, its COVID-19 vaccine candidate, as early as late 2020
Full Article